Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Sponsor
Shoucheng Ma
Study ID
NCT02829385
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib and XELOX combined treatment group — DRUG
    Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14) Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.

Study Details

This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer. All the participants will receive the treatment of Apatinib and XELOX combination regimen.

Key Dates

Start date
Jun 30, 2016
Status verified
Jul 2016
Primary completion
Dec 31, 2017
Completion
Sep 30, 2018

Study Design

Enrollment
53 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib combined treatment group
    Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14) Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: up to 9 months ]

Central Contacts

Related Studies